Clinical trials: Pre-dementia
Grief
Experiencing Loss and Planning Ahead Study
The course of dementia over many years, gradual losses and uncertain life expectancy can lead to grief amongst family and friend carers.
- Trial name
- ELPAS (NCT03332979)
- Where
- United Kingdom
- Volunteers
- 150 people
- Sponsor
- University College, London
Alzheimer Disease
Pre-Clinical (Alzheimers) Diagnosis PCD = Optimum Outcomes OO
This Observational protocol will attempt to verify two recent and very critical concepts in ALZ Clinical Research by studying high-risk individuals who already are taking medications which may prevent the onset of ALZ.
- Trial name
- PCD=OOALZ (NCT02835716)
- Testing
- roflumilast, ustekinumab
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Millennium Magnetic Technologies, LLC
Alzheimers Disease, Inflammation
Alzheimers Disease and Neuromarkers in Patients With Acute Hip Fractures
The investigators explore the presence of AD factors beta-amyloid and tau in CSF and plasma to verify AD diagnosis in patients with acute hip fracture. Clinical dementia test is performed prior to operation.
- Conditions
- Alzheimers Disease, Inflammation, Hip Fracture
- Trial name
- ADhipfract (NCT02409082)
- Where
- Sweden
- Volunteers
- 400 people
- Sponsor
- Sahlgrenska University Hospital
PTSD, Depression
Violence Prevention for Adolescent Girls With Prior Maltreatment
The purpose of the study is to adapt and test an evidence-based trauma treatment program for adolescent girls with histories of child maltreatment.
- Conditions
- PTSD, Depression, Aggression, Victimization
- Trial name
- GAIN (NCT02765048)
- Testing
- GAIN Program
- Where
- 3 sites in United States
- Volunteers
- 312 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Prion Disease
PrP-targeting siRNA Safety & Mechanism Study
The purpose of this trial is to evaluate safety, tolerability, pharmacokinetics and pharmacodynamic impact of PrP-siRNA in symptomatic prion disease patients and in pre-symptomatic adults at genetic risk for prion disease.
- Trial name
- PRiSM (NCT07444580)
- Testing
- PrP-siRNA
- Where
- 5 sites in United States
- Volunteers
- 45 people
- Sponsor
- Broad Institute of MIT and Harvard
Huntington Disease
An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Participants Who Participated in Prior Roche and Genentech Sponsored Studies
This study will evaluate the long-term safety and tolerability of RO7234292 (RG6042) in participants who have completed other F.
- Trial name
- NCT03842969
- Testing
- RO7234292 (RG6042)
- Where
- 38 sites in United States, Austria and 6 more
- Volunteers
- 236 people
- Sponsor
- Hoffmann-La Roche
Agitation
Transbucal Dexmedetomidine for Prevention of Sevoflurane Emergence Agitation in Pre-school Children
The aim of this study is to evaluate the efficacy of transbucal dexmedetomidine given in preschool children undergoing tonsillectomy operations in the prevention sevoflurane agitation.
- Trial name
- NCT02720705
- Testing
- Dexmedetomidine, saline
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- Assiut University
Dementia, Dementia Alzheimers
Implementation of a Diagnostic Decision-aid for People With Memory Complaints and Their General Practitioners
In a mixed-methods design the investigators will study decision making processes and experiences regarding a diagnostic trajectory before and after the introduction of a patient decision aid for people with memory complaints…
- Conditions
- Dementia, Dementia Alzheimers, Dementia, Mild
- Trial name
- S-DeciDeD (NCT04531956)
- Testing
- Diagnostic decision aid s-decided
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- Maastricht University
Hydration
Feasibility of Using the Gatorade Sports Science Institute (GSSI) Labs App for Hydration Related Outcomes
This remote study will evaluate the feasibility of using the Gatorade Sports Science Institute (GSSI) Labs App for remotely collecting hydration related outcomes.
- Trial name
- NCT07005895
- Testing
- Hydration assessment via mobile app
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- PepsiCo Global R&D
Alzheimer's Disease
Detection of Disease-Related Changes in Pre-Symptomatic Alzheimer's Disease
The investigators are conducting a study to try to improve our ability to identify older adults who are at high-risk for progression to Alzheimer's disease, several years before they have symptoms that might reduce their quality…
- Trial name
- Scope (NCT01841905)
- Testing
- Observational Study
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Rhode Island Hospital
Neurodegenerative Diseases, Alzheimer Disease
Sociodemographic Factors and Criminal Behaviour Preceding Neurodegenerative Disease - Retrospective Register Study
In this retrospective register study, clinically classified individuals with neurodegenerative disease from the years 2010-2021 will be verified from the clinical records from KUH and Oulu University Hospital (OUH).
- Conditions
- Neurodegenerative Diseases, Alzheimer Disease, Frontotemporal Dementia, Lewy Body Disease
- Trial name
- DEGERWD (NCT06209515)
- Where
- Finland
- Volunteers
- 61,292 people
- Sponsor
- Kuopio University Hospital
Alzheimer Disease
Choline Effects - Pre-symptomatic AD
The purpose of this study is to test the safety, tolerability, and effects of choline in people with increased risk of Alzheimer's Disease (AD), also known as pre-symptomatic AD.
- Trial name
- NCT05880849
- Testing
- Choline
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Paul E Schulz
Alzheimer Disease, Mild Cognitive Impairment
Evaluation of a Computerized Complex Instrumental Activities of Daily Living Marker (NMI)
The proposed study is designed to evaluate the performance of the ALTOIDA™ System as a tool to assist physicians in diagnosing Alzheimer's Disease (AD) in real-world clinical settings.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Memory Disorders, Cognitive Impairment
- Trial name
- AltoidaML (NCT02843529)
- Testing
- Altoida: neuropsychological, MRI, EEG and CSF biomarkers
- Volunteers
- 548 people, healthy volunteers welcome
- Sponsor
- Altoida
Cognitive Symptom, Pre Senile Dementia
Compensatory Training to Support Brain Healthy Lifestyle Changes in Those at Risk for Alzheimer's Disease
The Researchers are trying to better understand if behavioral interventions can help improve memory compensation and engagement in healthy lifestyle behaviors in those with memory concerns but normal mental status exam.
- Conditions
- Cognitive Symptom, Pre Senile Dementia, Alzheimer Disease
- Trial name
- NCT04118985
- Testing
- Cognitive rehabilitation and health behavior change intervention, Self-implementation
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Alzheimer Disease, Cognitive Decline Due to Alzheimer Disease
Randomized Trial of Low-dose Naproxen in Cognitively Intact Persons at Risk of Alzheimer's Dementia
Two-year double-masked trial of over-the-counter dosage of naproxen sodium vs placebo in 200 cognitively normal participants with a parental or multiplex first-degree family history Alzheimer's disease (AD) dementia.
- Conditions
- Alzheimer Disease, Cognitive Decline Due to Alzheimer Disease, Mild Cognitive Impairment Due to Alzheimer Disease
- Trial name
- NCT02702817
- Testing
- Naproxen
- Where
- Canada
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Douglas Mental Health University Institute
Alzheimer's Dementia
Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Alzheimer's Dementia
This phase IIIb study is intended to implement a consistent treatment way for switching to Exelon transdermal patch from oral formulation of rivastigmine to stress the importance of (1) advantages of transdermal patch over…
- Trial name
- NCT01585272
- Testing
- ENA713
- Where
- 4 sites in Taiwan
- Volunteers
- 121 people
- Sponsor
- Novartis Pharmaceuticals
Healthy Volunteers
Methylphenidate and Cognitive Training in Elderly
Currently, there is no available drug to treat the symptoms of neurodegenerative and vascular cognitive disorders that affect millions of people worldwide.
- Trial name
- PACTE-1 (NCT03280251)
- Testing
- Methylphenidate, CogniPlus software, Pseudo cognitive training
- Where
- France
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- University Hospital, Lille
Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
Alzheimer's Disease Neuroimaging Initiative 2
The purpose of this study is to build upon the information obtained in the original Alzheimer's Disease Neuroimaging Initiative (ADNI1) and ADNI-GO (Grand Opportunity; a study funded through an NIH grant under the American…
- Conditions
- Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD), Significant Memory Concern (SMC), Early Mild Cognitive Impairment (EMCI)
- Trial name
- ADNI2 (NCT01231971)
- Testing
- Florbetapir, Flortaucipir
- Where
- 58 sites in United States, Canada
- Volunteers
- 1,182 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Alzheimer's Disease, Mild Cognitive Impairment
Observational Study of Cognitive Outcomes for Subjects Who Have Had Prior PET Amyloid Imaging With Florbetapir F 18 (18F-AV-45)
The primary objective of this protocol is to determine if brain amyloid imaged with florbetapir F 18 (18F-AV-45) PET scans is predictive of progressive cognitive impairment during the subsequent 36 months for groups of: normal…
- Trial name
- NCT00857506
- Testing
- florbetapir F 18
- Where
- 8 sites in United States
- Volunteers
- 152 people
- Sponsor
- Avid Radiopharmaceuticals
Brain Ischemia, Adverse Effect of Thrombolytic Drugs
Pre-stroke Cognitive Status and Thrombolytic Therapy
At the acute stage of cerebral ischaemia, the only effective drug that increases the proportion of patients who survive without dependency is thrombolytic therapy by intravenous (i.v.) tissue-plasminogen activator (t-PA).
- Conditions
- Brain Ischemia, Adverse Effect of Thrombolytic Drugs, Impaired Cognition, Dementia
- Trial name
- OPHELIE-COG (NCT01713491)
- Where
- 9 sites in France, Japan
- Volunteers
- 205 people
- Sponsor
- University Hospital, Lille